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transmission disequilibrium test (TDT). Considering the small
number of informative proband/parents pairs investigated (39
according to Table I, there appears to be an error in Table II and
in the text, where 41 heterozygotes are stated), we think that the
presented data would deserve a more cautious interpretation.
Psoriasis is a polygenic disease. In the last 3 y a number of
candidate regions have been identified on several chromosomes
(Tomfohrde et al, 1994; Nair et al, 1997; Trembath et al, 1997).
Particularly patients with type 1 psoriasis (positive family history,
disease onset ,40 y) show strong linkage to the MHC on the
short arm of chromosome 6 (Elder et al, 1994). The extended
haplotype Cw6-B57-DR7 is associated with the highest risk of
developing the disease (Schmitt-Egenolf et al, 1993). The TNF238.2
promoter polymorphism is part of this ancestral haplotype.
In the study by Traupe et al there is also significant increase of
the TNF238.2 variant among psoriasis patients compared to the
control group in our own study (15% compared with 3.5%;
p , 0.001). This allele frequency has been confirmed in another
German control population (4.8% in 123 healthy blood donors,
Arias et al, 1997) and a third independent group of controls
investigated by our group. The TNF238.2 allele frequency in the
German population is slightly lower than that reported from Italy
(7%, D’Alfonso and Richiardi, 1994).
In the Traupe study there is also a significant increase of the
TNF238.2 polymorphism among the parents (allele frequency 12%
compared with 3.5%, p , 0.01), which is not surprising because
42 individuals from this group were also suffering from psoriasis.
Unfortunately the authors do not present any data on this subgroup.
The overall lower TNF238.2 allele frequency in the Traupe
study is most likely due to the fact that 49% of the patients were
sporadic cases, whereas in both previous studies only patients with
a positive family history were included. Particularly this patient
group shows a strong association with the MHC (Elder et al, 1994).
The TDT investigates the frequency with which a certain allele
is transmitted to the offspring. Traupe et al found that in 39
informative proband/parents pairs the TNF238.2 allele was trans-
mitted to 63% of the probands (in comparision the TNF308.2
allele was transmitted in only 42% of the cases). Although these
data show segregation of the TNF238.2 polymorphism with
psoriasis they are not statistically significant; however, preferential
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To the Editor:
We are most concerned about the sequence of the putative variant
of proopiomelanocortin (POMC) in the human epidermis and in
epidermal cells as reported by Can et al (1998). Initially we were
quite surprised by the report of 28 base changes in a small region
of Exon 3 of the variant POMC cDNA compared with the well-
established human POMC cDNA sequence from the pituitary
gland. This number seemed to be a rather unusual amount of
polymorphism in this putative epidermal variant. Upon careful
examination of these 28 base substitutions it was confirmed that
the reported human epidermal POMC cDNA variant is identical
to that reported for mouse POMC cDNA alpha (Uhler and
Herbert, 1983; Uhler et al, 1983; Eberle, 1998). Table 1 presents
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inheritance of the TNF238.2 allele to 60%–70% of the offspring
would be in accordance with our current concept of psoriasis as a
polygenic disease with a disease concordance of 55%–70% among
monozygotic twins, knowing that this allele is just one of several
factors that confers disease susceptibility. In our opinion the number
of informative proband/parents pairs is too small to detect the
disease association with the TNF238.2 allele. Considering the high
percentage of sporadic cases and the small number of informative
proband/parents pairs, we would be interested to know whether
this study design would allow the association of the extended
haplotype Cw6-B57-DR7 with psoriasis, which has been recently
confirmed in a large study using the TDT (Jenisch et al, 1998), to
be detected.
Thomas Ho¨hler
I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-
Universita¨t Mainz, Mainz, Germany
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a comparison between these 28 base changes in human pituitary
POMC cDNA in Exon 3 with the proposed human skin POMC
cDNA variant and mouse POMC cDNA where the proposed skin
variant is identical to the mouse. This result could most likely be
accounted for by polymerase chain reaction errors introduced either
by the mouse pituitary cell line (AtT20) used as a positive control
throughout the in situ hybridization experiments, or from human
skin grafts onto the mice used in this study. It is obvious that
mouse cDNA must have been introduced erroneously into the
human cDNA reactions early in the experimental protocol, con-
sequently leading to the false positive result. Therefore we would
like to point out that the human epidermis and epidermal cells in
culture contain only the POMC cDNA previously established for
the pituitary gland and not a variant as reported by Can et al (1998).
Janis Ancans, Anthony J. Thody, John M. Wood,
Wayne D. Beazley, Karin U. Schallreuter
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Table I. Sites of polymorphism in POMC cDNA
Human pituitary POMC cDNA AGCGCGCCTACGATCGTCGCAGCCCAGC
Human skin POMC cDNA (variant) CTTATCTGGGTTCCTACTATCCAGTGCT
Mouse POMC cDNA CTTATCTGGGTTCCTACTATCCAGTGCT
Clinical and Experimental Dermatology, Department of
Biomedical Sciences, University of Bradford, Bradford, U.K.
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Reply
This is in response to Ancans et al’s letter addressing the recently
published article by Can et al (1998) on the presence of a putative
POMC mRNA variant in human epidermis.
It is true that polymerase chain reaction (PCR) may introduce
errors resulting in amplification of a wrong sequence as suggested
by Ancans et al; however, based on our findings and for the reasons
detailed below, we are very confident that the sequence we have
reported is correct and is not due to an error in sequencing or
contaminated mouse sequence.
PCR experiments were performed using cultured normal human
melanocytes and keratinocytes (obtained from neonatal foreskins)
from well-established laboratories of my collaborators, Zalfa Abdel-
Malek and Steven Boyce at the University of Cincinnati.
The primers used in PCR were designed using human exon 2
and 3 sequences of POMC, and RNA from human cells were
used in PCR experiments. A human POMC plasmid (pH – 0X3)
obtained from Dr. James Roberts (Mount Sinai Medical Center,
NY) was also used.
Mouse anterior pituitary tumor cells (AtT20) was used as a
positive control only in in situ hybridization experiments. In PCR,
these cells were used only in the beginning to optimize the
conditions for PCR and were omitted during subsequent PCR
experiments, contrary to the comments presented by Ancans et al.
PCR experiments, cloning and sequencing of PCR products
were carried out at least three different times (n 5 3) from each
cell type obtained from different donors without the inclusion of
AtT20 cells. Thus there was no chance of contamination by
mouse cells.
In addition, recently we designed the sense primer TAC ATC
CGG GCC TGC AAG CCC CA and the anti-sense primer TCC
TAA CTA CAG GCA GCT TTA AGA CGC based on the human
exon 3 sequence (Takahashi et al, 1983). These primers were used
to clone most of exon 3 of human POMC gene from human
melanocytes, keratinocytes, and normal human skin. A PCR
product of µ676 bp was obtained in these cells and tissues and in
the AtT20 cell line. The comparison of the sequence of this PCR
product revealed 85%–89% homology with human POMC exon
3 and 100% homology with mouse POMC exon 3. The sequence
analysis was carried out at least three times (n 5 3) using different
donors for melanocytes and keratinocytes and without including
AtT20 cells. Also, I would like to point out that the sequencing
was performed at two different facilities (University of Cincinnati
DNA Core Facility and Marshall University, West Virginia DNA
Core Facility) with identical results.
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The experiments described above and the experiments that were
published in this journal were carried out over a 2 y time period
and were performed independently by different laboratory staff
who used different sources of reagents and different donors of
human melanocytes, keratinocytes, and normal human skin and
without the inclusion of AtT20 cells. Given these conditions it is
highly unlikely, if not impossible, that the same error or contamina-
tion would be duplicated.
To us the data suggest the presence of a variant form of POMC
mRNA in human epidermis and epidermal cells in culture. This
phenomenon has been well documented in various tissues by
different investigators. For example, as is well documented in our
paper, larger POMC mRNA transcripts have been reported in
murine and hamster melanoma cells (Slominski, 1991), trout
pituitary (Salbert et al, 1992), and nonpituitary ACTH-producing
tumors, thymic carcinoid, and pancreatic tumors (Eberle, 1988).
On the other hand, shorter POMC mRNA transcripts (µ200–
400 bp less) have been documented in normal adrenal glands,
ovary, testis and thymus in animals (Jeannotte et al, 1987), and in
human tissues (DeBold et al, 1988, Gallinelli et al, 1995). Recently,
we have reported the presence of a shorter or truncated form of
POMC mRNA (µ0.9 kb) in mouse Thy11 dentritic cells
(Farooqui et al, 1995). It has been postulated that these truncated
forms of POMC mRNA transcripts may arise as a consequence of
alternative splicing, variation in the length of the poly1 (A) tail,
or use of alternative transcription initiation site (Oates and Herbert,
1984; Lacaze-Masmonteil et al, 1987). Although the functional
significance of the variant POMC mRNA is not clear, it appears
to vary in a tissue-specific manner. It is our future goal to isolate
and identify the different POMC products that may be processed
by this variant POMC mRNA in human skin.
Without actually comparing our results and experimental condi-
tions with those of Ancans et al that have not been published yet,
it remains impossible for anyone to make any judgments about the
validity of the results.
Jamal Farooqui
University of Cincinnati, Department of Dermatology,
Cincinnati, Ohio, U.S.A.
REFERENCES
Can G, Abdel-Malek Z, Porter-Gill PA, et al: Identification and sequencing of a
putative variant of proopiomelanocortin in human epidermis and epidermal
cells in culture. J Invest Dermatol 111:485–491, 1998
DeBold CR, Menefee JK, Nicholson WE, Orth DN: Pro-opiomelanocortin gene
is expressed in many normal human tissues and in tumors not associated with
ectopic adrenocorticotropin syndrome. Mol Endocrinol 2:862–870, 1988
Eberle AN: The Melanotropins. Basel: Karger, 1988, p. 38
Farooqui JZ, Medrano EE, Boissy RE, Tigelaar RE, Nordlund JJ: Thy-11 dendritic
cells express truncated form of POMC mRNA. Exp Dermatol 4:297–301, 1995
Gallinelli A, Garuti G, Matteo ML, Genazzani AR, Facchinetti F: Expression of
proopiomelanocortin gene in human ovarian tissue. Human Reprod 100:1085–
1089, 1995
Jeannotte L, Burbach JPH, Drouin J: Unusual proopiomelanocortin ribonucleic acids
in extrapituitary tissues: Intronless transcripts in testes and long poly (A) tails
in hypothalamus. Mol Endocrinol 1:749–757, 1987
Lacaze-Masmonteil T, Keyzer YD, Luton JP, Kahn A, Bertagna X: Characterization
of proopiomelanocortin transcripts in human nonpituitary tissues. Proc Natl
Acad Sci USA 84:7261–7265, 1987
Oates E, Herbert E: Sequence of porcine and rat proopiomelanocortin mRNA.
J Biol Chem 259:7421–7425, 1984
Salbert G, Chauveau I, Georgette B, Valotaise Y, Jego P: One of the trout
proopiomelanocortin messenger RNAs potentially encodes new peptides. Mol
Endocrinol 6:1605–1613, 1992
Slominski A: POMC gene expression in mouse and hamster melanoma cells. Febs
Lett 291:165–168, 1991
Takahashi H, Hakamata Y, Watanabe Y, Kikuno R, Miyata T, Numa S: Complete
nucleotide sequence of the human corticotropin-β-lipotropin precursor gene.
Nucl Acids Res 11:6847–6858, 1983
